CN115287278A - 一种枯草芽孢杆菌纤溶酶及其制备方法和抗氧化溶血栓组合物 - Google Patents
一种枯草芽孢杆菌纤溶酶及其制备方法和抗氧化溶血栓组合物 Download PDFInfo
- Publication number
- CN115287278A CN115287278A CN202210689796.0A CN202210689796A CN115287278A CN 115287278 A CN115287278 A CN 115287278A CN 202210689796 A CN202210689796 A CN 202210689796A CN 115287278 A CN115287278 A CN 115287278A
- Authority
- CN
- China
- Prior art keywords
- bacillus subtilis
- fibrinolytic enzyme
- thrombus
- plasmin
- peptone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000063299 Bacillus subtilis Species 0.000 title claims abstract description 66
- 235000014469 Bacillus subtilis Nutrition 0.000 title claims abstract description 66
- 101710196208 Fibrinolytic enzyme Proteins 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 230000002537 thrombolytic effect Effects 0.000 title claims abstract description 15
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 12
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 44
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical group C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 19
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 11
- 230000004792 oxidative damage Effects 0.000 claims abstract description 11
- 238000004321 preservation Methods 0.000 claims abstract description 8
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 7
- 229940012957 plasmin Drugs 0.000 claims description 18
- 239000001888 Peptone Substances 0.000 claims description 17
- 108010080698 Peptones Proteins 0.000 claims description 17
- 235000019319 peptone Nutrition 0.000 claims description 17
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000002518 antifoaming agent Substances 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 5
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 5
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 238000001471 micro-filtration Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 235000013402 health food Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 238000009825 accumulation Methods 0.000 abstract description 9
- 239000000679 carrageenan Substances 0.000 abstract description 9
- 229940113118 carrageenan Drugs 0.000 abstract description 9
- 235000010418 carrageenan Nutrition 0.000 abstract description 9
- 229920001525 carrageenan Polymers 0.000 abstract description 9
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract description 9
- 230000002792 vascular Effects 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 3
- 230000003966 vascular damage Effects 0.000 abstract 1
- 108010088842 Fibrinolysin Proteins 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 9
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 229940118019 malondialdehyde Drugs 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000003405 preventing effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940001501 fibrinolysin Drugs 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 229940086319 nattokinase Drugs 0.000 description 2
- 108010073682 nattokinase Proteins 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
- C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提出了一种枯草芽孢杆菌纤溶酶及其制备方法和抗氧化溶血栓组合物,属于枯草芽孢杆菌技术领域,由枯草芽孢杆菌Bacillussubtilis ZF01发酵制得,所述菌株保藏于中国典型培养物保藏中心,其保藏编号为CCTCC NO:M 2022132。本发明利用β‑烟酰胺单核苷酸与枯草杆菌纤溶酶组合物应用于角叉菜胶诱导小鼠血栓模型试验证明,β‑烟酰胺单核苷酸具有抗氧化效果,可降低角叉菜胶对血管的氧化损伤程度,缓解血栓形成。同时枯草杆菌纤溶酶也具有一定抗氧化水平,并且可以溶解因血管氧化损伤而已经形成的血栓,显著降低血栓积累程度,二者组合可协同作用于血管损伤诱发的血栓,且效果显著优于单一成分应用。
Description
技术领域
本发明涉及枯草芽孢杆菌技术领域,具体涉及一种枯草芽孢杆菌纤溶酶及其制备方法和抗氧化溶血栓组合物。
背景技术
β-烟酰胺单核苷酸(β-烟酰胺单核苷酸)是烟酰胺腺嘌呤二核苷酸(NAD+)的前体物质。NAD+在哺乳动物体内起到非常关键的作用。其中最为人们所知的是抗衰老方面的研究。主要表现在调控能量代谢、基因表达和修复。此外,研究证明通过口服β-烟酰胺单核苷酸可增加NAD+含量,促进血管再生、抗氧化、抗炎症等功效。
枯草杆菌纤溶酶是由枯草芽孢杆菌发酵产生的一种丝氨酸蛋白酶,具有口服溶解血栓的功效,在心血管疾病领域具有非常广阔的应用价值。其中被人们所熟悉的是纳豆菌发酵产生的纳豆激酶,纳豆菌隶属于枯草芽孢杆菌种,纳豆亚种。
众所周知,血栓性疾病是心血管疾病最主要表现,是治病率和致死率最高的疾病。其中脑卒中、冠心病最为严峻。而血栓性疾病的致病因素是各种内因和外因引起的血管壁损伤导致血液凝血引起的。而血管损伤便伴随着内皮细胞氧化,从而进一步加剧损伤和血栓积累。基于β-烟酰胺单核苷酸抗衰老抗氧化功效,以及本公司枯草杆菌纤溶酶的纤溶作用和溶栓功效。通过两种成分的组合应用能够协同防治血栓性疾病,一方面可以预防或延缓血管壁氧化和损伤,预防血栓形成;另一方面还可以溶解血管内已经形成的血栓,达到溶栓功效。通过β-烟酰胺单核苷酸和枯草杆菌纤溶酶的组合应用,协同解决血栓性疾病,既能预防又能治疗。对心血管疾病的防治具有重要的社会意义,并且具备广阔的市场应用前景和价值。
发明内容
本发明的目的在于提出一种枯草芽孢杆菌纤溶酶及其制备方法和抗氧化溶血栓组合物,β-烟酰胺单核苷酸与枯草杆菌纤溶酶组合物可相互协同作用防控血栓性疾病,一方面抗氧化抗损伤,预防血栓形成和积累;另一方面同时还可以溶解已经形成的血栓,达到预防和治疗的双重目的并且安全无副作用。
本发明的技术方案是这样实现的:
本发明提供一种枯草芽孢杆菌纤溶酶,由枯草芽孢杆菌Bacillus subtilis ZF01发酵制得,所述菌株保藏于中国典型培养物保藏中心,其保藏编号为CCTCC NO:M 2022132。
作为本发明的进一步改进,所述发酵包括固体发酵和液体发酵,发酵干燥后所得枯草杆菌纤溶酶活性不低于10000FU/g。
本发明进一步保护一种上述枯草芽孢杆菌纤溶酶的制备方法,包括以下步骤:
(1)制备蛋白胨培养基,110-120℃灭菌20-40min,备用;
(2)将枯草芽孢杆菌Bacillus subtilis ZF01菌种按重量比2-4%接种到蛋白胨培养基中,35-38℃发酵18-30h;
(3)将发酵液经过离心、微滤、浓缩后喷雾干燥即得枯草芽孢杆菌纤溶酶,枯草芽孢杆菌纤溶酶活性>10000FU/g。
作为本发明的进一步改进,所述蛋白胨培养基的成分与质量百分比含量为:蛋白胨2%、葡萄糖3%、磷酸氢二钠1%、磷酸二氢钠0.1%、硫酸镁0.05%、无水氯化钙0.02%、消泡剂0.1%、余量为水。
作为本发明的进一步改进,具体包括以下步骤:
(1)制备蛋白胨培养基,向培养基中加入以下质量百分比成分:蛋白胨2%、葡萄糖3%、磷酸氢二钠1%、磷酸二氢钠0.1%、硫酸镁0.05%、无水氯化钙0.02%、消泡剂0.1%、余量为水,115℃灭菌30min,备用;
(2)将枯草芽孢杆菌Bacillus subtilis ZF01菌种按重量比3%接种到蛋白胨培养基中,37℃发酵24h;
(3)将发酵液经过离心、微滤、浓缩后喷雾干燥即得枯草芽孢杆菌纤溶酶,枯草芽孢杆菌纤溶酶活性>10000FU/g。
本发明进一步保护一种抗氧化溶血栓组合物,由以下原料制备而成:β-烟酰胺单核苷酸和权利要求1所述枯草芽孢杆菌纤溶酶。
作为本发明的进一步改进,由以下原料按质量百分比制备而成:β-烟酰胺单核苷酸5-20%、权利要求1所述枯草芽孢杆菌纤溶酶80-95%。
作为本发明的进一步改进,所述β-烟酰胺单核苷酸来源于植物提取、化学合成或者生物酶催化。
本发明进一步保护一种上述的抗氧化溶血栓组合物在制备预防及治疗血管氧化损伤、血栓性疾病的食品、保健食品和药品中的应用。
本发明进一步保护一种枯草芽孢杆菌Bacillus subtilis ZF01菌种,所述菌种保藏于中国典型培养物保藏中心,其保藏编号为CCTCC NO:M 2022132。
本发明具有如下有益效果:枯草芽孢杆菌Bacillus subtilis ZF01菌株为本公司特有菌株,从发酵性豆制品中分离获得,隶属于枯草亚种。发酵亦可以产生一种新型枯草杆菌纤溶酶,命名为枯草杆菌纤溶酶ZF。本发明经研究证明纤溶酶ZF具有纤溶和溶栓作用。纤溶酶ZF可通过刺激血管内皮细胞产生组织型纤溶酶原激活剂(t-PA),t-PA将纤溶酶原激活为纤溶酶,溶解纤维蛋白,能够直接溶解血栓。并且纳豆激酶还能抑制血小板的聚集,降低血液的粘稠度,保护血管内皮,预防动脉粥样硬化等。
各种原因引起的血管氧化损伤是血栓形成的根本原因,而血栓又是心血管疾病最主要诱因。小鼠腹腔注射角叉菜胶可氧化损伤血管内皮细胞,从而导致血栓积累。本发明中,利用β-烟酰胺单核苷酸与枯草杆菌纤溶酶组合物应用于角叉菜胶诱导小鼠血栓模型试验证明,β-烟酰胺单核苷酸具有抗氧化效果,可降低角叉菜胶对血管的氧化损伤程度,从而缓解血栓形成。同时枯草杆菌纤溶酶也具有一定抗氧化水平,并且可以溶解因血管氧化损伤而已经形成的血栓,显著降低血栓积累程度。二者组合应用,可协同作用于血管损伤诱发的血栓,且效果显著优于单一成分应用。
本发明β-烟酰胺单核苷酸与枯草杆菌纤溶酶组合物可相互协同作用防控血栓性疾病,一方面抗氧化抗损伤,预防血栓形成和积累;另一方面同时还可以溶解已经形成的血栓,达到预防和治疗的双重目的并且安全无副作用。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
枯草芽孢杆菌Bacillus subtilis QK02菌种,所述菌种保藏于中国典型培养物保藏中心,保藏地点为中国武汉武汉大学,其保藏编号为CCTCC NO:M 2022132,保藏日期为2022年2月18日。
β-烟酰胺单核苷酸原料来源于本公司重组生物酶催化并纯化后获得,纯度超过90%。
实施例1
原料组成(质量百分比):β-烟酰胺单核苷酸占比5%,枯草芽孢杆菌纤溶酶粉占比95%。
枯草芽孢杆菌纤溶酶按以下发酵过程制备。
(1)制备蛋白胨培养基,向培养基中加入以下质量百分比成分:蛋白胨2%、葡萄糖3%、磷酸氢二钠1%、磷酸二氢钠0.1%、硫酸镁0.05%、无水氯化钙0.02%、消泡剂0.1%、余量为水,115℃灭菌30min,备用;
(2)将枯草芽孢杆菌Bacillus subtilis ZF01菌种按重量比3%接种到蛋白胨培养基中,37℃发酵24h;
(3)将发酵液经过离心、微滤、浓缩后喷雾干燥即得枯草芽孢杆菌纤溶酶,枯草芽孢杆菌纤溶酶活性>10000FU/g。
实施例2
与实施例1的不同之处在于原料配比不同。
β-烟酰胺单核苷酸占比10%,枯草芽孢杆菌纤溶酶粉占比90%。
实施例3
与实施例1的不同之处在于原料配比不同。
β-烟酰胺单核苷酸占比15%,枯草芽孢杆菌纤溶酶粉占比85%。
实施例4
与实施例1的不同之处在于原料配比不同。
β-烟酰胺单核苷酸占比20%,枯草芽孢杆菌纤溶酶粉占比80%。
对比例1
与实施例1的不同之处在于原料配比不同。
枯草芽孢杆菌纤溶酶粉占比100%。
对比例2
与实施例1的不同之处在于原料配比不同。
β-烟酰胺单核苷酸占比100%。
试验例1
本发明实施例以β-烟酰胺单核苷酸与枯草杆菌纤溶酶组合物对角叉菜胶损伤小鼠诱导尾静脉血栓的治疗为例。小鼠腹腔注射角叉菜胶可氧化损伤血管,从而诱导血管内血栓的形成。小鼠尾部可以观察到血栓,尾部变成黑色。可以通过尾部血栓引起的黑色长度所占全部尾长的比例反应血栓的严重程度。具体过程如下:
选取健康小鼠120只,体重20±5g,雌雄各半,在开始实验前,将购买的大鼠适应性喂养一周后,随机将小鼠分为8组,每组15只。第一组为正常组;第二组为模型组;第三组为枯草芽孢杆菌纤溶酶组;第四组为β-烟酰胺单核苷酸组;第五组为实施例1组;第六组为实施例2组;第七组为实施例3组;第八组为实施例4组。除第一组腹腔注射生理盐水外,其余组别小鼠腹腔注射50mg/kg的角叉菜胶导致血管氧化损伤,诱导血栓形成。
注射角叉菜胶后,第一组正常组,第二组模型组,灌胃生理盐水。其余组别分别按照分组说明灌胃单一原料或不同比例组合物,灌胃剂量为1000mg/只小鼠,连续灌胃1周,第7天统计小鼠尾部血栓长度所占全部尾长比例(%)。同时眼眶采血检测血清丙二醛(MDA)含量。
表1
注:*P<0.05、**P<0.01vs模型组。
通过表1数据可知,正常组与模型组相比尾部血栓长度占比与MDA含量都达到极显著差异(p<0.01),说明动物模型组实验成功。角叉菜胶导致血管壁氧化损伤,从而诱发血栓形成。
第三组MDA含量小于模型组(p<0.05),说明枯草杆菌纤溶酶也具有一定的抗氧化水平,血管内皮保护功效。第六、七、八组MDA含量与模型组相比都达到极显著差异(p<0.01),且含量均低于单独灌胃β-烟酰胺单核苷酸和纤溶酶的第三、四组。说明组合物灌胃效果好于单一成分灌胃,具有协同抗氧化效果。
尾部血栓长度占比能够反映血管内血栓积累的严重程度。单独灌胃β-烟酰胺单核苷酸成分的第四组与模型组相比虽然可显著降低MDA含量,从而降低有血管壁的氧化损伤引起的血栓积累程度(p<0.05)。单独灌胃纤溶酶成分的第三组与模型组相比,尾部血栓长度占比达到显著差异水平(p<0.01)。且第五、六、七、八组的血栓积累严重程度低于单独灌胃纤溶酶的第三组。说明β-烟酰胺单核苷酸与纤溶酶组合应用优于单一成分应用。
综上,β-烟酰胺单核苷酸与枯草杆菌纤溶酶组合应用对于因血管氧化损伤诱发的血栓形成具有显著的治疗效果,且效果优于单一成分应用。且当β-烟酰胺单核苷酸与纤溶酶比例达到15:85时效果更显著。上述结果说明两种组分组合应用具有协同的抗氧化、抗血栓、溶血栓效果,对于心血管疾病的防控具有重要意义。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种枯草芽孢杆菌纤溶酶,其特征在于,由枯草芽孢杆菌Bacillus subtilis ZF01发酵制得,所述菌株保藏于中国典型培养物保藏中心,其保藏编号为CCTCC NO:M 2022132。
2.根据权利要求1所述枯草芽孢杆菌纤溶酶,其特征在于,所述发酵包括固体发酵和液体发酵,发酵干燥后所得枯草杆菌纤溶酶活性不低于10000FU/g。
3.一种如权利要求1或2所述枯草芽孢杆菌纤溶酶的制备方法,其特征在于,包括以下步骤:
(1)制备蛋白胨培养基,110-120℃灭菌20-40min,备用;
(2)将枯草芽孢杆菌Bacillus subtilis ZF01菌种按重量比2-4%接种到蛋白胨培养基中,35-38℃发酵18-30h;
(3)将发酵液经过离心、微滤、浓缩后喷雾干燥即得枯草芽孢杆菌纤溶酶,枯草芽孢杆菌纤溶酶活性>10000FU/g。
4.根据权利要求3所述的制备方法,其特征在于,所述蛋白胨培养基的成分与质量百分比含量为:蛋白胨2%、葡萄糖3%、磷酸氢二钠1%、磷酸二氢钠0.1%、硫酸镁0.05%、无水氯化钙0.02%、消泡剂0.1%、余量为水。
5.根据权利要求3所述的制备方法,其特征在于,具体包括以下步骤:
(1)制备蛋白胨培养基,向培养基中加入以下质量百分比成分:蛋白胨2%、葡萄糖3%、磷酸氢二钠1%、磷酸二氢钠0.1%、硫酸镁0.05%、无水氯化钙0.02%、消泡剂0.1%、余量为水,115℃灭菌30min,备用;
(2)将枯草芽孢杆菌Bacillus subtilis ZF01菌种按重量比3%接种到蛋白胨培养基中,37℃发酵24h;
(3)将发酵液经过离心、微滤、浓缩后喷雾干燥即得枯草芽孢杆菌纤溶酶,枯草芽孢杆菌纤溶酶活性>10000FU/g。
6.一种抗氧化溶血栓组合物,其特征在于,由以下原料制备而成:β-烟酰胺单核苷酸和权利要求1所述枯草芽孢杆菌纤溶酶。
7.根据权利要求6所述抗氧化溶血栓组合物,其特征在于,由以下原料按质量百分比制备而成:β-烟酰胺单核苷酸5-20%、权利要求1所述枯草芽孢杆菌纤溶酶80-95%。
8.根据权利要求5所述抗氧化溶血栓组合物,其特征在于,所述β-烟酰胺单核苷酸来源于植物提取、化学合成或者生物酶催化。
9.一种如权利要求6-8任一项所述的抗氧化溶血栓组合物在制备预防及治疗血管氧化损伤、血栓性疾病的食品、保健食品和药品中的应用。
10.一种枯草芽孢杆菌Bacillus subtilis ZF01菌种,其特征在于,所述菌种保藏于中国典型培养物保藏中心,其保藏编号为CCTCC NO:M 2022132。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210689796.0A CN115287278B (zh) | 2022-06-17 | 2022-06-17 | 一种枯草芽孢杆菌纤溶酶及其制备方法和抗氧化溶血栓组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210689796.0A CN115287278B (zh) | 2022-06-17 | 2022-06-17 | 一种枯草芽孢杆菌纤溶酶及其制备方法和抗氧化溶血栓组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115287278A true CN115287278A (zh) | 2022-11-04 |
CN115287278B CN115287278B (zh) | 2023-11-10 |
Family
ID=83821041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210689796.0A Active CN115287278B (zh) | 2022-06-17 | 2022-06-17 | 一种枯草芽孢杆菌纤溶酶及其制备方法和抗氧化溶血栓组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115287278B (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030026798A1 (en) * | 1999-11-13 | 2003-02-06 | Zimmerman Thomas P. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
WO2006116949A1 (fr) * | 2005-04-30 | 2006-11-09 | Chengdu Di'ao Jiuhong Pharmaceutical Factory | Nouvelle souche du bacillus subtilis et son utilisation dans la préparation de médicament pour traiter la thrombose |
US20110111092A1 (en) * | 2006-11-22 | 2011-05-12 | Sam Pin Lee | Bacillus subtilis ha producing fibrinolytic enzyme and mucilage highly, method of preparing fermented soybeans using the same strain, and soybeans prepared by the method |
WO2015186068A1 (en) * | 2014-06-02 | 2015-12-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Preparation and use of crystalline beta-d-nicotinamide riboside |
WO2016188091A1 (zh) * | 2015-12-11 | 2016-12-01 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物 |
CN107536844A (zh) * | 2017-06-30 | 2018-01-05 | 上海风劲生物医药科技有限公司 | 烟酰胺单核苷酸在制备预防或治疗rtPA血管并发症的药物中的应用 |
WO2018211051A1 (en) * | 2017-05-18 | 2018-11-22 | Dsm Ip Assets B.V. | Microbial production of nicotinamide riboside |
CN110251665A (zh) * | 2019-07-24 | 2019-09-20 | 武汉真福医药股份有限公司 | 枯草杆菌纤溶酶在治疗深静脉血栓药物中的应用 |
CN111840526A (zh) * | 2020-08-01 | 2020-10-30 | 武汉真福医药股份有限公司 | 枯草杆菌纤溶酶在治疗颈动脉粥样硬化性斑块上的应用 |
CN111996208A (zh) * | 2020-05-25 | 2020-11-27 | 南宁邦尔克生物技术有限责任公司 | 一种利用重组枯草芽孢杆菌生产烟酰胺单核苷酸的方法 |
-
2022
- 2022-06-17 CN CN202210689796.0A patent/CN115287278B/zh active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030026798A1 (en) * | 1999-11-13 | 2003-02-06 | Zimmerman Thomas P. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
WO2006116949A1 (fr) * | 2005-04-30 | 2006-11-09 | Chengdu Di'ao Jiuhong Pharmaceutical Factory | Nouvelle souche du bacillus subtilis et son utilisation dans la préparation de médicament pour traiter la thrombose |
US20080193973A1 (en) * | 2005-04-30 | 2008-08-14 | Chengdu Di'ao Jiuhong Pharmaceutical | Bacillus Subtilis Strain and its Use in Preparing Pharmaceuticals for Treating Thrombosis |
US20110111092A1 (en) * | 2006-11-22 | 2011-05-12 | Sam Pin Lee | Bacillus subtilis ha producing fibrinolytic enzyme and mucilage highly, method of preparing fermented soybeans using the same strain, and soybeans prepared by the method |
WO2015186068A1 (en) * | 2014-06-02 | 2015-12-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Preparation and use of crystalline beta-d-nicotinamide riboside |
WO2016188091A1 (zh) * | 2015-12-11 | 2016-12-01 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物 |
WO2018211051A1 (en) * | 2017-05-18 | 2018-11-22 | Dsm Ip Assets B.V. | Microbial production of nicotinamide riboside |
CN107536844A (zh) * | 2017-06-30 | 2018-01-05 | 上海风劲生物医药科技有限公司 | 烟酰胺单核苷酸在制备预防或治疗rtPA血管并发症的药物中的应用 |
CN110251665A (zh) * | 2019-07-24 | 2019-09-20 | 武汉真福医药股份有限公司 | 枯草杆菌纤溶酶在治疗深静脉血栓药物中的应用 |
CN111996208A (zh) * | 2020-05-25 | 2020-11-27 | 南宁邦尔克生物技术有限责任公司 | 一种利用重组枯草芽孢杆菌生产烟酰胺单核苷酸的方法 |
CN111840526A (zh) * | 2020-08-01 | 2020-10-30 | 武汉真福医药股份有限公司 | 枯草杆菌纤溶酶在治疗颈动脉粥样硬化性斑块上的应用 |
Non-Patent Citations (2)
Title |
---|
PING XIAO等: "A Fibrinolytic Enzyme Produced by Bacillus subtilis Using Chickpea (Cicer arietinum L.) as Substrate", 《ADVANCE JOURNAL OF FOOD SCIENCE AND TECHNOLOGY》, vol. 978, no. 12, pages 1294 - 1300 * |
刘彩平: "产纤溶酶菌DC-YJ11的筛选鉴定、混合发酵优化及纤溶酶的分离纯化", 《中国优秀硕士学位论文全文数据库》, no. 2011, pages 024 - 60 * |
Also Published As
Publication number | Publication date |
---|---|
CN115287278B (zh) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dubey et al. | Isolation, production, purification, assay and characterization of fibrinolytic enzymes (Nattokinase, Streptokinase and Urokinase) from bacterial sources | |
KR101925096B1 (ko) | 숙취해소효소 분말의 제조방법 및 이를 포함하는 숙취해소용 조성물 | |
EP1927365A1 (en) | A new bacillus subtilis strain and its use in preparing medicine for treating thrombosis | |
CN112999261B (zh) | 一种舒缓动脉硬化的纳豆发酵组合物及其制备方法和应用 | |
US10597632B2 (en) | Animal product-free culture medium for bacteria of the genus Clostridium and a process for producing supernatant comprising one or more collagenolytic and gelatinolytic proteases | |
TW201821611A (zh) | 黑酵母菌、生產β-葡聚糖之培養基與方法、黑酵母菌培養物與含其組成物 | |
CN103820368A (zh) | 醋酸菌冻干菌粉的制备方法及用途 | |
CN112972488B (zh) | 一种具有抗高尿酸血症活性的岩藻寡糖及其制备方法和应用 | |
CN117264840A (zh) | 一株短乳杆菌xy8及其在制备抗衰老和改善痛风食品药品中的应用 | |
CN103468666A (zh) | 一种提高液体复合酶稳定性的方法 | |
CN115287278A (zh) | 一种枯草芽孢杆菌纤溶酶及其制备方法和抗氧化溶血栓组合物 | |
JP3225840U (ja) | 高活性ナットウキナーゼ粉末の作製システム | |
CN104163685B (zh) | 一种添加金莲花渣的蛹虫草子实体培养基 | |
TW201233339A (en) | Food for preventing thrombotic diseases | |
CN113116941B (zh) | 一种可缓解2型糖尿病的益生菌、益生元复合制剂及其制备方法 | |
CN105153174B (zh) | 一种吡喃骈吲哚类化合物及其制备方法和应用 | |
CN107997081A (zh) | 一种木糖醇果脯冻的加工方法 | |
CN117721033B (zh) | 一株发酵粘液乳杆菌ks6及其在制备抗炎和助睡眠食品药品中的应用 | |
Sizer | Medical applications of microbial enzymes | |
CN117384788B (zh) | 一株唾液联合乳杆菌sm4及其在制备美白和降胆固醇食品药品中的应用 | |
CN112760346B (zh) | 一种高免疫活性酵母细胞壁多糖的提取方法 | |
CN109200058A (zh) | 聚古罗糖醛酸丙酯硫酸盐在制备抗凝血药物中的应用 | |
CN107502625B (zh) | 极地海洋微生物产生的几种溶栓化合物的制备方法及用途 | |
CN117946938A (zh) | 一株植物乳植杆菌sm3及其在制备降血糖和助睡眠食品药品中的应用 | |
CN117264844A (zh) | 一株降解尿酸副干酪乳杆菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |